The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Eris Lifesciences's Dividend Payout Ratio for the
months ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Eris Lifesciences's Dividend Payout Ratio or its related term are showing as below:
During the past 13 years, the highest Dividend Payout Ratio of Eris Lifesciences was 0.29. The lowest was 0.14. And the median was 0.21.
BOM:540596's Dividend Payout Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.38 * Ranked among companies with meaningful Dividend Payout Ratio only.
During the past 12 months, Eris Lifesciences's average Dividends Per Share Growth Rate was -100.00% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Eris Lifesciences was 36.80% per year. The lowest was 6.90% per year. And the median was 21.85% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Eris Lifesciences (BOM:540596) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Eris Lifesciences Dividend Payout Ratio Related Terms
Eris Lifesciences Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Eris Lifesciences's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540596 vs ZTS, UTHR: Dividend Payout Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eris Lifesciences Dividend Payout Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Eris Lifesciences's Dividend Payout Ratio falls into.
Eris Lifesciences Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Eris Lifesciences's Dividend Payout Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eris Lifesciences (BOM:540596) has a Dividend Payout Ratio of 0.00 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Eris Lifesciences and its competitors. Over the past decade, Eris Lifesciences' Dividend Payout Ratio has ranged from 0.14 to 0.29. According to the industry distribution chart, Eris Lifesciences ranks #999999 out of 445 companies in the Drug Manufacturers industry.
Is Eris Lifesciences' Dividend Payout Ratio too high?
Eris Lifesciences' current Dividend Payout Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 0.29. Based on the distribution chart, Eris Lifesciences ranks #999999 out of 445 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Eris Lifesciences has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' Dividend Payout Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eris Lifesciences ranks #999999 out of 445 companies for Dividend Payout Ratio. This places Eris Lifesciences in the lower half of its industry. The industry median Dividend Payout Ratio is 0.38. Historically, Eris Lifesciences' own Dividend Payout Ratio has ranged from 0.14 to 0.29 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Drug Manufacturers company?
The median Dividend Payout Ratio among Drug Manufacturers companies is 0.38, based on 445 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Eris Lifesciences and its competitors. For the Drug Manufacturers industry, the median Dividend Payout Ratio is 0.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eris Lifesciences's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (BOM:540596) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,649.16, compared to a current price of ₹1,432.00 — trading 13.2% below its estimated fair value. The current Dividend Payout Ratio is 0.00. Eris Lifesciences' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Eris Lifesciences (BOM:540596), the current Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eris Lifesciences (BOM:540596) Overvalued in 2026?
Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued.
The current stock price of ₹1,432.00 is trading 13.2% below its estimated GF Value™ of ₹1,649.16.
GuruFocus considers Eris Lifesciences to be Modestly Undervalued.
Key valuation signals for BOM:540596:
Dividend Payout Ratio: 0.00
GF Value™: ₹1,649.16 vs. price of ₹1,432.00 (13.2% below fair value)
No single metric tells the full story. See the BOM:540596 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
93GF Score
Get the complete analysis for BOM:540596
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540596 has been successfully added to your 
